Maravai (MRVI) director Susannah Gray receives 46,293-share stock unit award

Rhea-AI Filing Summary

GRAY SUSANNAH reported acquisition or exercise transactions in this Form 4 filing.

MARAVAI LIFESCIENCES HOLDINGS, INC. director Susannah Gray received a grant of 46,293 shares of Class A Common Stock in the form of restricted stock units under the 2020 Omnibus Incentive Plan. Her direct holdings increased to 216,200 shares after this award, which vests in full after one year or at the 2027 annual meeting.

Insider Trade Summary

Net Buyer: 46,293 shares

Net Buy 1 txn

Insider GRAY SUSANNAH

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	46,293	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 216,200 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Figures

RSU grant size: 46,293 shares Grant price: $0.0000 per share Post-transaction holdings: 216,200 shares +2 more

5 metrics

RSU grant size 46,293 shares Restricted stock units granted May 26, 2026

Grant price $0.0000 per share Equity compensation award, not market purchase

Post-transaction holdings 216,200 shares Total Class A Common Stock held directly after grant

Vesting period 1 year or 2027 meeting Vests earlier of one year from grant or 2027 annual meeting

Transaction code A Grant, award, or other acquisition of non-derivative equity

Key Terms

restricted stock units, 2020 Omnibus Incentive Plan, annual meeting of stockholders, Class A Common Stock

4 terms

restricted stock units financial

"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Omnibus Incentive Plan financial

"awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026"

annual meeting of stockholders financial

"vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders"

Class A Common Stock financial

"security_title: "Class A Common Stock" in the reported transaction"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/28/2026 - 06:27 PM Learn about SEC filing dates

FAQ

What did Maravai (MRVI) director Susannah Gray report in this Form 4?

Director Susannah Gray reported receiving 46,293 restricted stock units of Maravai Class A Common Stock. These units were granted as equity compensation and increased her direct holdings to 216,200 shares following the transaction.

How many Maravai (MRVI) shares did Susannah Gray acquire in this grant?

Susannah Gray acquired 46,293 shares of Maravai Class A Common Stock in the form of restricted stock units. The grant price was recorded as $0.0000 per share, reflecting a compensation award rather than an open-market purchase.

When do Susannah Gray’s new Maravai (MRVI) restricted stock units vest?

The restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the date of Maravai’s 2027 annual meeting of stockholders. This creates a single cliff-vesting event tied to time and the shareholder meeting.

What is Susannah Gray’s total Maravai (MRVI) share ownership after this Form 4?

After the award, Susannah Gray directly holds 216,200 shares of Maravai Class A Common Stock. This total includes the 46,293 newly granted restricted stock units reported in the transaction, as disclosed in the Form 4 filing.

Was Susannah Gray’s Maravai (MRVI) Form 4 transaction a market purchase or sale?

The transaction was a grant of restricted stock units classified as a compensation award, not a market purchase or sale. The Form 4 uses transaction code A, indicating a grant, award, or other acquisition from the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAY SUSANNAH

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/26/2026		A		46,293(1)	A	$0	216,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Susannah Gray	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)